Neucyte, Inc. – Trademark Portfolio

Entity Type: 03

Neucyte, Inc. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include NEUCYTE and SYNFIRE. The owner is based in Mountain View, CA.

319 N Bernardo Ave

Mountain View, CA 94043

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

SYNFIRE
SYNFIRE
Registered 2016
NEUCYTE
NEUCYTE
Registered 2016
NEUCYTE
NEUCYTE
Registered 2016

Trademark Classifications

Neucyte, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (2 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Neucyte, Inc. have?

Neucyte, Inc. has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Neucyte, Inc. file in?

Neucyte, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are Neucyte, Inc.'s most well-known trademarks?

Neucyte, Inc.'s registered trademark portfolio includes well-known marks such as NEUCYTE and SYNFIRE. These are among 3 currently registered trademarks in the portfolio.

What is Neucyte, Inc.'s trademark registration success rate?

Neucyte, Inc. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.